Latest News

Eli Lilly raises annual revenue forecast as Zepbound quarterly sales cross $1 billion

Eli Lilly on Thursday raised its annual earnings forecast and sales of its popular weightloss drug Zepbound crossed $1 billion for the first time in a. quarter.

The drugmaker now anticipates adjusted earnings of $16.10 to. $ 16.60 per share for 2024, compared to its previous forecast of. $ 13.50 to $14.

Lilly and Danish competing Novo Nordisk are racing to. increase production capability to satisfy unprecedented need for. their popular weight-loss drugs that have actually been shown to assist. clients lose as much as 20% of their weight typically.

Experts have said the companies will likely divide the U.S. market approximately 50-50 by the end of 2024, as Lilly increases its. making capability and closes the gap with Novo.

Lilly has stated it expected production in its brand-new. production lines to start over 2024 and for a new plant in. Concord, North Carolina, to begin operations towards the end of. the year.

Financier interest in these treatments has propelled Lilly's. market value to over $700 billion in current months. The stock. has actually increased about 32% up until now this year and was up 9% in premarket. trading. Some experts expect the marketplace for weight- loss. treatments to strike $150 billion by the early 2030s.

Quarterly sales of Mounjaro was available in at $3.09 billion, while. Zepbound sales were $1.24 billion.

Experts had on average forecasted sales of $2.49 billion for. Mounjaro and $930.8 million for Zepbound for the quarter. They. anticipate the drugs to make a combined $15 billion this year.

(source: Reuters)